Rebuilt antigen catalog

Draft: tumor-source comparability and specialized normal/developmental coverage remain under review. Scrutiny of the original 250 Cancer Antigens only.

638 CTA, 260 Cancer Antigen only, 22 Reproductive Antigen only, 714 Other and 18,259 Unsafe.

Filterable protein table · All category changes · Exact comparison scope

Rebuilt counts

Cancer Antigens include 898 proteins; Reproductive Antigens include 660. Their intersection is CTA and their union contains 920 Target candidates.

Other contains 659 review, 40 sequence, 15 expression. A curated published target nomination is retained for 408 CTAs and 24 Cancer Antigens only. Broader paper coverage also includes biology, normal-expression findings and other evidence.

Category changes

Released category Rebuilt category Proteins
CTA CTA 580
CTA Other 7
CTA Reproductive Antigen only 20
Other CTA 58
Other Cancer Antigen only 260
Other Other 707
Other Reproductive Antigen only 2
Unsafe Unsafe 18259

New CTAs: AMELY, H2BW2, KRT37, UCP1, ANKRD60, SRMS, OR1E2, GALR3, OCM2, TTLL8, CIB3, POTED, OR2B2, PROKR1, HOXD12, DEFB125, OR52D1, MAGEB17, DGAT2L6, MROH2A, SPATA31A6, AADACL3, HUS1B, OR14A16, OR51C1, KRTAP4-1, GLYATL3, KRTAP5-10, MAS1L, ARSH, KRTAP19-8, KRTAP20-4, TRIM64C, ZNF705D, DEFB115, TRIM51G, ZNF816-ZNF321P, SUPT20HL1, RAB6D, PRR23C, KRTAP5-7, ENSG00000249773, KRTAP5-9, ENSG00000255432, ENSG00000255835, KDM4F, ENSG00000258691, ENSG00000267140, SPATA31A3, SPATA31A7, SPATA31A5, ENSG00000279983, RPS4Y2, FAM240B, OOSP1, OOSP3, ENSG00000285566, POTEB/2.

Former CTAs now requiring review: CALHM3, TAF11L12, TRIM75, TAF11L14, PRAMEF18, TAF11L11, TAF11L13.

Reproductive Antigens only

15 have potentially qualifying tumor measurements but unresolved patient independence; none reaches the single-sample threshold. The remaining 7 do not meet either cancer RNA rule.

Protein Tumor maximum TPM Normal comparison TPM Cancer assessment
SLC25A52 5.58 2.97 Patient identity unresolved
ZSWIM2 2.74 1.52 Patient identity unresolved
GARIN3 6.5 2.07 Patient identity unresolved
CDY1 1.6 0 Below cancer rule
CDY1B 0.3 0.1 Below cancer rule
MAGEB5 2.09 0.0392 Patient identity unresolved
FAM47B 2.25 0 Patient identity unresolved
VN1R2 12.3 7.79 Patient identity unresolved
OR8G1 2.69 2.5 Below cancer rule
DEFB113 2.27 0 Patient identity unresolved
ZNF705B 3.78 0 Patient identity unresolved
OR5H1 1.4 2.3 Below cancer rule
FAM237A 7.8 2.26 Patient identity unresolved
H2AL1Q 4.02 2.6 Patient identity unresolved
P3R3URF 16.5 3.4 Patient identity unresolved
PTTG1IP2 3.23 0.3 Patient identity unresolved
ENSG00000274944 13.5 2.8 Patient identity unresolved
CCDC201 5.38 1.1 Patient identity unresolved
HSFX3 4.88 1.8 Patient identity unresolved
MSANTD5 3.43 2.2 Below cancer rule
CIMIP3 1.2 0.2 Below cancer rule
ENSG00000289809 0.0679 4.5 Below cancer rule

Evidence and reproduction

The comparison uses source-native TPM and maxima of supported tissue/cell summaries. It does not correct cross-study batch effects. NUTM's stored three-sample matrix fails the nonnegative-TPM check and is listed in the coverage ledger.

Full protein decisions · All member genes · Normal comparison values · Tumor witnesses · Paper claims · Input hashes.

The pinned HPA download receipt supplies exact URLs, paths and SHA-256 hashes for the newly retrieved native-TPM tables. With the pinned source files in the paths listed in inputs.json, run:

python scripts/rebuild_target_catalog.py
python scripts/render_target_catalog.py
python scripts/build_target_selection_report.py

The builder verifies the pinned tumor matrices, re-resolves source identities and assesses all proteins. Temporary tumor matrices stay outside the published report. The new catalog is available through target_selection.results(); the cta_selection API and existing sequence downloads retain the 1.36.0 snapshot.